Content Status

Type

Linked Node

H5Content
Content

The shorter injectable-containing MDR/RR-TB Regimen consists of 4 to 6 months of intensive phase with high dose moxifloxacin, Kanamycin/Amikacin (injectable), Ethionamide, Clofazimine, Pyrazinamide, high dose isoniazid and ethambutol and a 5-month continuation phase with high dose moxifloxacin, Clofazimine, Pyrazinamide and Ethambutol. This regimen can be written in the following abbreviated form.

(4-6) Mfxh, Km/Am, Eto, Cfz, Z, Hh, E/ (5) Mfxh, Cfz, Z, E

Mfxh- High dose moxifloxacin

Km/Am- Kanamycin/Amikacin

Eto- Ethionamide

Cfz-Clofazimine

Z- Pyrazinamide

Hh -High dose Isoniazid 

E- Ethambutol

Note:

  • If the intensive phase is prolonged, the injectable agent (Km/Am) is only given three times a week in the extended intensive phase;
  • Neither replacement of drug (except the use of Am instead of Km) nor extension of treatment duration (beyond 11 months) is permitted; and
  • Pyridoxine is to be given as per weight band.

 

Resources

Assessments

Question     Answer 1     Answer 2     Answer 3     Answer 4     Correct answer     Correct explanation     Page id     Part of Pre-test     Part of Post-test
Which of these statements is true about the Shorter Injectable-containing MDR/RR-TB regimen and duration? Any of the drugs can be replaced Treatment can be extended beyond 11 months if required Amikacin cannot be used in place of Kanamycin Pyridoxine has to be given as per weight band 4 Pyridoxine is given to counteract the effects of high dose Isoniazid which may cause peripheral neuropathy by Vit B6 deficiency      
Mfxh stands for  High dose isoniazid High dose Moxifloxacin Moxifloxacin resistance Isoniazid resistance 2 Mfxh stands for High dose Moxifloxacin      

Content Creator

Reviewer


Linked Approval Requests

No content linked currently.